PTCT insider sales: Matthew Klein reports multiple stock sales

PTCT reported Form 144 sale notices for common stock by Matthew Klein.

Rhea-AI Filing Summary

PTCT reported Form 144 sale notices for common stock by Matthew Klein. The filings list multiple sales of common shares in December 2025 and January 2026, including specific transactions of 12/02/2025 (3,428 shares) and 12/30/2025 (8,089 shares). The entries show proceeds for each sale in U.S. dollars.

Insights

Securities Compliance Counsel

Form 144 filings record reported insider sales; they are routine disclosures required under Rule 144.

These entries list multiple dispositions by Matthew Klein of common stock with per-trade share counts and corresponding proceeds, for example 12/02/2025 (3,428 shares, 271062.93) and 12/30/2025 (8,089 shares, 619921.55). The notices document prior sales rather than new grants.

Timing and method details are transaction-level; any legal or compliance implications depend on holding period and volume limitations stated in Rule 144. Subsequent filings or broker records would confirm settlement and any continuing transfer restrictions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the PTCT Form 144 filing show?

The filing shows reported sales of PTCT common stock by Matthew Klein. It lists multiple transactions with dates, share counts and proceeds, for example 12/02/2025 (3,428 shares, 271062.93) and 12/30/2025 (8,089 shares, 619921.55).

Who is the reported seller in the PTCT Form 144?

The reported seller is Matthew Klein. The filing provides his address and multiple sale entries across December 2025 and January 2026 with per-trade share counts and dollar proceeds for each transaction.

Which dates and share amounts are included in the PTCT sale disclosures?

Disclosed sale dates include 12/02/2025 (3,428 shares), 12/30/2025 (8,089 shares), 01/06/2026 (5,149 shares), 01/07/2026 (3,016 shares), and 01/08/2026 (2,514 shares). Each row lists corresponding proceeds in dollars.

Do the PTCT entries show how proceeds will be used?

The entries list proceeds per sale in U.S. dollars but do not state use of proceeds. The Form 144 records the disposition details—dates, share counts, and proceeds—without allocating proceeds to specific company uses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:21 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001808968
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	PTC THERAPEUTICS, INC.
SEC File Number	001-35969
Address of Issuer	500 WARREN CORPORATE CENTER DRIVE WARREN NEW JERSEY 07059
Phone	9082227000
Name of Person for Whose Account the Securities are To Be Sold	Klein Matthew B.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	7371	511227.50	80288305	02/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/17/2026	Restricted Stock Vesting	Issuer			7371	02/17/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/02/2025	3428	271062.93
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	12/30/2025	8089	619921.55
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/06/2026	5149	396203.19
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/07/2026	3016	233691.14
Matthew Klein 500 Warren Corporate Center Drive Warren NJ 07059	Common	01/08/2026	2514	192193.04

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Matthew Klein
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)